Inovio Pharmaceuticals/$INO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Inovio Pharmaceuticals

Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.

Ticker

$INO
Sector
Health
Primary listing
NASDAQ

Employees

112
Headquarters
Plymouth Meeting, United States
Website
www.inovio.com

INO Metrics

BasicAdvanced
$91m
-
-$1.56
-
-

What the Analysts think about INO

Analyst ratings (Buy, Hold, Sell) for Inovio Pharmaceuticals stock.

INO Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37bn
-39.75%
Net income
$45bn
107.52%
Profit margin
37.65%
6.78%

INO Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

INO News

AllArticlesVideos
Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm

Newsfile Corp·2 weeks ago
Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances

Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances

MarketBeat·3 weeks ago
Hantavirus cases spark surge in pharma and biotech stocks — here's why

Hantavirus cases spark surge in pharma and biotech stocks — here's why

CNBC·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs